Background. When the indication for surgery of highly advanced gastric cancer is considered, careful selection of the patients is important. In addition to tumor-nodemetastasis factors and peritoneal lavage cytology (CY), which are important predictors of prognosis, detection of circulating tumor cells (CTCs) could be another potential marker. Methods. This study prospectively evaluated CTCs using a semi-automated immunomagnetic separation system (CellSearch) for 136 patients with advanced gastric cancer to determine the frequency of CTC positivity. For 123 patients who also had their CY evaluated, the significance of both CTC and CY, was investigated as a potential biomarker to predict progression-free survival (PFS) or to monitor the therapeutic effect. Results. In 25 patients (18.4 %), CTCs were positive. Positive CTC counts were more common for tumors with diffuse histologic type and distant metastasis. The PFS of CTC-positive patients was significantly shorter than that of CTC-negative patients (hazard ratio 2.03; P = 0.016). A multivariate analysis of 123 patients showed that CTC and CY as well as performance status and macroscopic distant metastasis were independent factors for PFS. When both CTC and CY were converted to negative values by therapeutic interventions, long-term PFS was achieved.
Conclusions. Detection of CTCs was an independent predictor of a shorter PFS in advanced gastric cancer. For selecting patients who require intensive treatment, CTCs could be a valuable biomarker. The combined status of CTC and CY would be useful in selecting patients for radical surgery. Further investigation with a larger number of patients is necessary to establish the importance of CTCs.
Gastric cancer is a leading cause of cancer death in the world. Surgery with postoperative adjuvant chemotherapy is a standard treatment for localized advanced gastric cancer according to the recent Japanese guidelines. 1 Neoadjuvant chemotherapy followed by surgery also is a promising approach used frequently in Western countries. 2 The prognosis for patients with a good response to chemotherapy is better than that for patients with a poor response. 3 When the tumor is chemosensitive, even metastatic patients have the possibility to undergo curative resection and achieve long-term survival. 4, 5 When the indication for surgery of highly advanced gastric cancer is considered, careful selection of patients who could benefit from surgery is very important. The clinical decision usually is based on the diagnosis determined using the tumor-node-metastasis (TNM) factors. However, even after curative surgery, recurrence could happen for tumors that have been diagnosed as early-stage disease. Therefore, we need more dependable biomarkers to predict the prognosis for patients with gastric cancer.
Detection of free cancer cells in the peripheral blood circulation [circulating tumor cells (CTCs)] could be a potential prognostic marker. Although the existence of CTCs has been reported in several types of cancer, its significance has not been well established because of its high false-positive rate and the nonviability of isolated cancer cells. In recent studies indicating their relevance in breast and colorectal cancer, CTCs were detected using a semi-automated immunomagnetic separation system (CellSearch) that provides highly reproducible results. 6, 7 To date, only a few studies have evaluated CTCs in gastric cancer using the CellSearch system (Janssen Diagnostics, Raritan, NJ, USA). 8, 9 Evaluation of peritoneal free cancer cells could be another useful selection tool because it is known to be a strong prognostic factor in gastric cancer. 10 The current Japanese gastric cancer classification and the International Union Against Cancer (UICC)/American Joint Committee on Cancer (AJCC) cancer staging system both classify gastric cancer with positive peritoneal lavage cytology (CY1 in Japanese classification and Cyt? in UICC staging system) as stage 4 disease. 11, 12 However, recent studies have shown that a significant proportion of patients with positive peritoneal lavage cytology (CY) achieved longterm survival with the combination of surgery and chemotherapy. 5, 13, 14 Therefore, surgical resection could be considered at least for some patients with positive CY. However, the optimal indication remains controversial.
In this prospective study, we evaluated CTCs and CY in patients with advanced gastric cancer. The main purpose of this study was to determine the frequency of CTC positivity in advanced gastric cancer and to determine whether CTC is a significant independent predictor of progressionfree survival (PFS). The secondary aim was to evaluate the relationship between CTC positivity and several clinical factors and to evaluate the clinical significance of cytologic detection of cancer cells in the circulation or peritoneal cavity as a biomarker to predict patient survival or to monitor therapeutic effect.
PATIENTS AND METHODS

Study Design
This prospective study was conducted at Kyoto University Hospital. The inclusion criteria specified histologically proven adenocarcinoma of the stomach diagnosed as T2 or higher, age of 20 years or older, and provision of written informed consent. The exclusion criteria ruled out previous treatment of gastric cancer and multiple primary cancers. The main purpose of this study was to determine the frequency of CTC positivity in advanced gastric cancer and to determine whether CTC is a significant predictor of PFS of patients with advanced gastric cancer. The secondary aim was to evaluate the relationship between CTC positivity and several clinical factors and to evaluate the clinical significance of cytologic detection of cancer cells in the circulation or peritoneal cavity as a biomarker to predict patient survival or to monitor therapeutic effect.
Sample size considerations were based on the estimated survival difference between patients with negative and positive CTCs. When the 3-year PFS rate of each group was estimated to be respectively 72 and 44 % and the frequency of CTCs was estimated as to be 30 % based on previous studies of breast cancer, 6 109 patients were required for a two-tailed log-rank test at 5 % significance and 80 % power.
We determined the sample size to be 120 patients during 3 years including a safety margin, and the accrual started in July 2008. The study protocol was approved by the institutional review board of Kyoto University (E-443). Due to the lower frequency of patients with CTCs and fewer accruals, the study period was extended to 4.75 years, and a total of 140 patients were enrolled by March 2013.
Patient Evaluation and Follow-up Assessment
Before the initial intervention, all patients were evaluated by multiple detector computed tomography (MDCT) scans of the neck, chest, abdomen, and pelvis, as well as by upper endoscopy, upper gastrointestinal series, serum carcinoembryonic antigen (CEA), and CA19-9. Patients with large tumors or bulky lymph node metastasis underwent staging laparoscopy for evaluation of CY and dissemination. The age, sex, performance status, histologic type, clinical TNM factors, and clinical stage according to the 7th version of the TNM classification were documented for each patient. 15 Peritoneal lavage was performed during the staging laparoscopy or during initial surgery using 50 mL of saline, and lavage fluid was collected from the Douglas' pouch, the left subphrenic space, or both for CY.
All the patients were followed up regularly at the outpatient unit to check for symptoms suggesting recurrence or progression of disease. At least every 3 months, MDCT scans were performed for measurement of tumors when the initial treatment was chemotherapy. After patients had undergone surgery, MDCT scans were performed at least every 6 months for patients with pathologic stage 2 disease or higher for the first 3 years. For patients with pathologic stage 1 disease, the MDCT scan was conducted annually.
Other methods including ultrasonography, gastrointestinal series, endoscopy, magnetic resonance imaging (MRI), and positron emission tomography with [18F]-fluorodeoxyglucose (FDG-PET) also were performed to determine the diagnosis if necessary. Relapse or progression of the disease was determined by evaluation of these images according to the response evaluation criteria in solid tumors (RECIST). 16 Histologic evaluation of the surgical specimen was performed according to the Japanese classification of gastric carcinoma. 12 Progressionfree survival (PFS) was defined as the time from the date of registry to the date of disease progression, relapse after surgery, or death from any cause. Overall survival (OS) was defined as the time from the date of registry to the date of death from any cause. Patient follow-up data were locked on 31 March 2014.
Isolation and Detection of CTCs
Peripheral blood was collected for evaluation of CTCs before the initial intervention (staging laparoscopy, surgery, or chemotherapy). Blood samples were drawn into 10-mL evacuated CellSave tubes (Veridex LLC, Raritan, NJ, USA). Samples were sent to the in-hospital laboratory and processed within 72 h. The CellSearch System (Veridex LLC) was used for the detection and counting of CTCs in 7.5 mL of peripheral blood samples.
Among the cells isolated with EpCAM-coated magnetic beads (Janssen Diagnostics, Raritan, NJ, USA), CTCs were defined as intact cells that stained positive for CK8/18/19 antibody and negative for CD45 antibody. These cells were counted without prior knowledge of the patient's clinical status. When the number of CTCs was less than four, independent counting was performed by another investigator, and only cells defined as CTCs by both investigators were included. For patients with positive CTCs, follow-up blood sampling and analysis of CTCs were performed 1-2 weeks after the initial treatment (chemotherapy or surgery).
Statistical Analysis
Categorical data were compared with the v 2 test, and continuous variables were compared using Student's t test. All P values lower than 0.05 were considered to be statistically significant. Multivariate analysis was performed to compare the CTC-negative and -positive groups using the logistic regression models to estimate the odds ratio for each factor. For survival analyses, the Kaplan-Meier method was used with the log-rank test for univariate analyses. Cox proportional hazards models were used for multivariate analyses, and the hazard ratio (HR) was estimated. All statistical analyses were performed using SPSS Statistic 19 software (IBM, Armonk, NY, USA).
RESULTS
CTC Count and Clinical Factors
Written consent was obtained from 140 patients. One patient had a history of chemotherapy and did not meet the inclusion criteria. Analysis of CTCs failed for three patients because of sampling error. The CTCs were positive in 25 (18.4 %) of 136 patients whose CTCs were successfully counted. The number of CTCs per 7.5 mL of blood in the CTC-positive patients ranged from 1 to 1123. In the CTC-positive patients, the median CTC count was four (Supplemental Fig. 1 ).
The relationships between the status of CTCs and the clinical factors were analyzed and summarized in Table 1 . A positive CTC count was more common in tumors with diffuse histologic type (P = 0.044) and distant metastasis (P = 0.004). The detection ratio of CTCs was as high as 33 % (13/39) for patients with distant metastasis, compared with 12.4 % (12/97) for patients without distant metastasis. Multivariate analysis using variables with P values lower than 0.20 showed that distant metastasis had the highest odds ratio [2.96; 95 % confidence interval (CI) 0.97-9.00], although the P value did not reach significance.
We also evaluated the relationship between clinicopathologic factors and numbers of CTCs to clarify the Table 1 ).
CTCs and Patient Survival
All but two patients were followed successfully until their death or 31 March 2014. The follow-up rate was 98.5 %. The median follow-up period was 26 months. To determine the number of CTCs that most clearly distinguished the patients with rapid progression of disease from those with slow progression, receiver-operating characteristic (ROC) curve analysis was performed. When the cutoff value was set at one CTC per 7.5 mL, the balanced error rate was minimal (Supplemental Fig. 2) . At this level, the P value of the Cox proportional hazards model signifying the difference between two survival curves showing rapid and slow progression of disease also was minimal (P = 0.018). Thus, a cutoff of one CTC per 7.5 ml of blood was chosen as a significant level for distinguishing patients with a poor prognosis from those with a better prognosis.
The PFS of the patients with a CTC level of 1 higher was significantly shorter than that of the patients with a CTC level of 0 (HR 2.03; 95 % CI 1.13-3.66; P = 0.016; Fig. 1a ). The OS of the patients with a CTC level of 1 or higher also was significantly worse than that of the patients with negative CTCs (HR 2.20; 95 % CI 1.120-4.03; P = 0.009; Fig. 1b) .
Analysis of Prognostic Factors
For 13 of the 136 patients, chemotherapy was initiated without staging laparoscopy to evaluate CY status. To identify significant prognostic factors among several clinical factors, including CY, 123 patients whose CTC and CY were analyzed successfully before the initial therapeutic intervention were included in the subsequent analysis. Of these patients, 57 underwent radical gastrectomy first without evaluation by staging laparoscopy. The remaining 66 patients initially underwent staging laparoscopy, laparoscopic bypass, or both. After staging laparoscopy/laparoscopic bypass, 3 patients underwent surgery, 1 patient chose best supportive care, and the remaining 62 patients underwent chemotherapy first. Of the latter patients, 44 eventually had surgery. All the patients were followed up regularly to check for recurrence or progression at the outpatient unit during the study period (Supplemental Fig. 3) . Two patients were lost to follow-up evaluation at 84 and 839 days, respectively. The dropout rate was 1.5 %.
The Kaplan-Meier method and the log-rank test were used to evaluate the effect of several clinical factors on PFS. The findings showed that PFS was significantly shorter for T4 tumors, lymph node metastasis, diffuse histologic type, macroscopic distant metastasis, CTCpositive status, and CY-positive status. Multivariate analysis using Cox proportional hazards models with variables that had a P value lower than 0.20 in the univariate analysis showed that performance status, macroscopic distant metastasis, CTC-positive status, and CY-positive status were independent prognostic factors ( Table 2) .
Uni-and multivariate analyses also were performed to evaluate the effect of clinical factors on OS. The same factors that were correlated with shorter PFS were associated with shorter OS. Multivariate analyses showed that performance status and macroscopic distant metastasis were independent prognostic factors ( Table 3) . 
Cytologic Detection of Cancer and Prognosis
To evaluate the impact of cytologic detection of gastric cancer in either the peripheral blood (CTC) or the peritoneal cavity (CY) on the prognosis of patients, we classified the status of CTC and CY into four categories: negative for both factors (CTC = 0 and CY = 0; n = 80), positive for CTC alone (CTC C 1 and CY = 0; n = 15), positive for CY alone (CTC = 0 and CY = 1; n = 20), and positive for both factors (CTC C 1 and CY = 1; n = 8). All but 3 of 28 CYpositive patients had received induction chemotherapy. The reasons for not receiving induction chemotherapy were age of 86 years (n = 1) and gastrectomy without staging laparoscopy (n = 2). Kaplan-Meier PFS curves of the four groups are shown in Fig. 2 . When the CY factor was negative, the PFS was similar between the patients who were CTC-negative (CTC = 0 and CY = 0) and those who were CTC-positive (CTC C 1 and CY = 0) (P = 0.555). By contrast, when the CY factor was positive, the PFS of the CTC-negative patients (CTC = 0 and CY = 1) was significantly better than that of the double-positive patients (CTC = 1 and CY = 1; P \ 0.001).
To characterize the patients in each category, the relationship between several clinicopathologic factors and the Table 2 ). In the CY-positive patients, all tumors were T4, and the histology was the diffuse type in all but three patients. We also analyzed the relationship between chemosensitivity and the status of CTC, CY, or both in 40 patients who had received induction chemotherapy, and the clinical response was evaluable. The clinical objective response was correlated with the status of CTC and CY. Especially, responses were more often observed in the CYnegative patients than in the CY-positive patients (Supplemental Table 3 ).
CTC as a Monitoring Marker for Therapeutic Intervention
Of 25 CTC-positive patients, 17 underwent induction chemotherapy. In 12 of these patients, the CTC was recounted after two or three courses of chemotherapy. The CTC counts after chemotherapy decreased in all the patients compared. In six patients, the CTCs disappeared completely ( Supplemental Fig. 4) . The clinical response in 10 patients with target lesions was evaluated according to the RECIST criteria. Seven patients achieved partial response (PR), and three patients had stable disease (SD). Disappearance of CTCs was achieved in five of seven patients with PR compared with one of three patients with SD.
Among the CTC-positive patients at baseline, CTC and CY status after induction chemotherapy, surgery, or both was obtained for 16 patients. In seven of these patients, both CTCs and CY were proven to be negative after chemotherapy, surgery, or both. The PFS of the seven patients was much better than that of those remaining positive for either factor ( Fig. 3 ; P = 0.002).
DISCUSSION
In this prospective study, CTCs were detected in 18 % of patients with advanced gastric cancer. The detection of CTCs was as high as 33 % in metastatic patients, but we also detected CTCs in 11 % of patients with resectable tumor. Regarding the histologic type, CTCs were detected twice as often in the diffuse type as in the intestinal type. These results are consistent with a recent meta-analysis of CTCs in gastric cancer. 17 It is difficult to speculate the reasons why CTC-positive cases are dominant with the diffuse histologic type. However, in our series, CTCs were detected more often in patients with peritoneal metastasis (9/25, 36 %) than in patients with liver metastasis (1/5, 20 %). Although the intestinal type is known to be associated with liver metastasis, probably tumor cells are mainly in the portal blood flow in such cases and not often detected in the peripheral blood.
Survival analyses showed that both OS and PFS were significantly shorter for patients with CTCs than for those without CTCs. Among several clinical factors, multivariate analysis showed that the presence of CTCs and CY, performance status, and macroscopic distant metastasis were independent predictors of shorter PFS. These data suggest that CTCs and CY are more reliable factors than clinical tumor (T) stage or lymph node (N) stage for selecting a certain group of patients for intensive treatment. Notably, the similar multivariate analysis for OS did not show the significance of CTCs and CY as prognostic factors. One of the reasons for this discrepancy is that the current study was designed to detect the difference in PFS between CTCnegative and -positive patients. To evaluate whether CTCs are an independent predictor for shorter OS, longer followup periods are needed to obtain a more mature survival curve.
Notably, the presence of CTCs was not only a predictor of PFS but also a useful biomarker for monitoring the therapeutic effect in gastric cancer. Although the number of patients in this study was too small to evaluate CTCs as a monitoring marker, changes in the status of CTCs seemed to correlate well with the objective response to chemotherapy. These results are consistent with those of a previous study investigating patients with metastatic gastric cancer. 9 Negative conversion of CTCs by therapeutic intervention also was associated with better survival of patients. These data strongly indicate that CTCs could become a valuable biomarker for making a difficult clinical decision (i.e., the indication for radical surgery after induction chemotherapy for marginally resectable gastric cancer).
In highly advanced gastric cancer, the assessment of CY and peritoneal dissemination by staging laparoscopy currently is recommended by the National Comprehensive Cancer Network therapeutic guidelines in United States. 18 Tumors positive for CY are classified as stage 4 in both the UICC/AJCC and the Japanese classification. 1, 11 However, initial surgical resection still is performed frequently in Japan, where staging laparoscopy is not in routine practice. For patients who are CY positive but without gross distant metastasis, surgical resection followed by chemotherapy is considered to be a standard treatment because about 20 % of patients achieve long-term survival. 13 However, the current study clearly indicated that when the status of CTCs was used in combination with CY, the prognosis for CTC-negative patients was significantly better than for patients positive for both CY and CTC factors. It would be very useful if we could select these patients before initial resection and provide more intensive treatment based on evaluation of the CTC and CY status.
This study also demonstrated an improved prognosis for patients in whom both CTC and CY factors were converted successfully to negative status after therapeutic intervention. When patients with highly advanced disease exhibit an excellent response to initial therapy, evaluation of both CTCs and CY could provide valuable information when the utility of surgical intervention is considered.
This study had several limitations. First, no consensus exists about the proper cutoff value for diagnosing CTCpositive cases. For breast cancer, five CTCs often are used as a proper cutoff. 6 For gastric cancer patients, the number of CTCs in each case tends to be smaller than for breast cancer patients. In previous studies of CTCs in gastric cancer, Hiraiwa et al. 19 used two CTCs whereas Uenosono et al. 8 used one CTC as the cutoff. We determined the cutoff as one CTC by ROC curve analysis, which is the standard method for assessing the proper cutoff value in a diagnostic test. Our cutoff needs to be evaluated with other data sets to determine whether it is generally acceptable.
Second, because the decision for treatment was made according to the preference of doctors and patients, treatments were heterogeneous. It may not be fair to compare survivals between groups with different treatments. However, the CTC-positive patients were more heavily treated than the CTC-negative patients, and yet the survival time was shorter. This finding strongly suggests that the prognosis for CTC-positive patients was much poorer indeed.
Third, because the CellSearch system captures CTCs using EpCAM, some CTCs can escape the detection due to epithelial-mesenchymal transition. However, we believe that the CTCs detected in this study represent an important and viable population because CTC-positivity was closely related to distant metastasis and poorer prognosis for patients.
In conclusion, CTCs were detected in a significant proportion of patients with advanced gastric cancer in this study. Detection of CTCs was an independent predictor of shorter PFS and could be a useful biomarker in the selection of patients who require intensive treatment or would benefit from radical surgery. To establish the usefulness of CTCs as a biomarker to aid in the clinical decision process for advanced gastric cancer, further study with a greater number of patients is necessary.
